Pharmacological reversal of synaptic and network pathology in human MECP2-KO neurons and cortical organoids.
Ontology highlight
ABSTRACT: Duplication or deficiency of the X-linked MECP2 gene reliably produces profound neurodevelopmental impairment. MECP2 mutations are almost universally responsible for Rett syndrome (RTT), and particular mutations and cellular mosaicism of MECP2 may underlie the spectrum of RTT symptomatic severity. No clinically approved treatments for RTT are currently available, but human pluripotent stem cell technology offers a platform to identify neuropathology and test candidate therapeutics. Using a strategic series of increasingly complex human stem cell-derived technologies, including human neurons, MECP2-mosaic neurospheres to model RTT female brain mosaicism, and cortical organoids, we identified synaptic dysregulation downstream from knockout of MECP2 and screened select pharmacological compoun
SUBMITTER: Trujillo CA
PROVIDER: S-EPMC7799367 | biostudies-literature | 2021 Jan
REPOSITORIES: biostudies-literature
ACCESS DATA